

Dr David Andrew Good

Date of Birth: - 20 January 1976

12 Hastings Close

CALAMVALE QLD 4116

Home: - (07) 3711 7657; Mobile: - (041) 1631 033;

Work: - (07) 3623 7657; Email: - david.good@acu.edu.au

Qualifications

1998 – 2003 **Doctor of Philosophy:** Griffith University, Brisbane, Australia.
Research component undertaken at the Princess Alexandra Hospital,
Department of Diabetes and Endocrinology, Brisbane, Australia.

1997 **First Class Honours:** Griffith University, Brisbane, Australia.
Research component undertaken at the CSIRO Division of Tropical
Agriculture, Brisbane Australia.

1994 – 1996 **Bachelor of Science:** Griffith University, Brisbane, Australia.

Experience

2010 – current **Senior Lecturer:** Anatomy and Preclinical sciences, School of Allied
Health, Australian Catholic University

I am currently the National Team Leader or Lecturer in Charge for a number of units within the School of Allied Health. These include Physiotherapy Anatomy 1 and 2, Physiotherapy Pathophysiology and Musculoskeletal Structure and Function. I have also previously been the National Team Leader for Physiotherapy Honours Practice 2 and Health Care Ethics for Physiotherapy Honours, Clinical Exercise Physiology for Physiotherapists and Physiotherapy Practice 2.

Until 2020 I was the Discipline of Physiotherapy First Year Advisor. In this role, some of the tasks I was required to do were to:

- Select an appropriate student/s from the first years.
- Organise staff-student representative meetings and provide feedback.
- Map assessment tasks for each unit across the semester in preparation for unit moderation and ratification at CIC meeting. Flag any concerns with Deputy Head of School.
- Support student progression.
- Be the first point of contact for students and staff with issues/queries related to curriculum.
- Monitor student application for extensions and/or special consideration where these apply to more than one unit at the year level

- Monitor student attendance in consultation with LIC's at year level, especially where this is impacting several units
- Liaise with LICs to identify students who have not been attending practical or tutorial classes at the beginning week 4 and advise the campus Course Co-ordinator.
- Facilitate activities to build a sense of community amongst the students
- Organise an inter-disciplinary social event (with the other Allied Health disciplines)

For my two Physiotherapy Anatomy subjects, I also run anatomy wet labs which predominately use human cadavers. In these classes I am responsible for the teaching and demonstrating of various structures on the specimens as well as ensuring the health and safety of each student. It has also been my responsibility to help first year students with the confronting nature of seeing and handling human cadavers for the first time. As part of my role, I also ensure that each specimen is handled with the utmost respect from all students.

In 2020, due to COVID-19, I was responsible for adapting my units to be delivered fully online. As this had not been previously done at ACU I was required to use innovation to be able convert all face-to-face teaching to an online format. This was particularly challenging with practical classes that had been previously taught using cadavers. I was able to achieve this by using different websites and software (like Complete Anatomy, Acland's video atlas, Kenhub and Teach Me Anatomy) that enable the visualisation of anatomy.

I am also responsible for maintaining the student learning site and provide resources including online quizzes and guided tutorials to supplement face-to-face teaching. I received considerable positive feedback and comments in student evaluations on the quality and helpfulness of these resources.

In the early stages of my teaching at ACU, I was responsible for introducing iPads into practical and tutorial classes in order to supplement learning with cadavers. This enabled all students' access to high quality anatomy apps, particularly from 3D4Medical (now owned by Elsevier). I am also currently exploring the use of the virtual reality app in teaching anatomy, which I am aiming to write a proposal in 2021 for the introduction for its use at ACU.

As a senior lecturer, I continually support and guide other staff in their role as lecturer in charge and/or national team leader and also provide help with teaching and IT enquiries. I also regularly assisted the former National Course Coordinator (Jennifer Murphy) in her role. Some of the processes I am familiar with include application for credit (RPL), students with special needs, special considerations, assessment

deferment, academic dishonesty, student misconduct, university admissions, timetabling, and assessment review panels.

At the end of 2011, I established the National Honours program for physiotherapy and served as the National School of Physiotherapy Honours Coordinator until 2017. I also led the development of the honours program within the school. As part of this role I was responsible for the design and writing of course material, selection of honours students, the coordinate the potential projects and supervisors, organisation of the letters of offer to honours students and advice and support to fellow staff in the supervision of honours students and support the honours students.

I have taken a leading role in developing assessment items and content for Health Care Ethics for Physiotherapy Honours. As part of this I was a named investigator on a **Teaching Development Grant** titled “Developing, implementing and evaluating a pedagogical model to promote interprofessional learning (IPL) and practice capabilities within undergraduate FHS students.”

I was also the team leader for a successful **Teaching Development Grant for the development of case studies**. Through my suggestion we developed a series of video case studies that could be horizontally and vertically integrated into multiple units throughout the 4 year physiotherapy degree.

In order to align some of my research interests with the school, I have established a Pain Research Team and was successful in obtaining \$40,000 of research grants.

Towards the end of 2012 I established and chaired the School of Physiotherapy Research Committee for three years. Through this committee I lead the school in research activities and discussions and monitored outputs and report these to the FHS standing committee. I have also served as a peer reviewer for many staff members ethics application prior to formal submission to the ethics committee.

I have played an active role in the recent curriculum development committee for course review. In this I have chaired a sub-committee on the preclinical sciences which has resulted in the writing of two new units.

I have or currently serve on a number of University committees and different levels.

- University level: Human Research Ethics Committee
- Faculty level: Internationalisation Committee
- Faculty level: Honours Review Committee
- School level: Curriculum Implementation Committee
- School level: Research Committee (established and chaired this committee for two years)

2008 - current **Senior Research Fellow/Head**, Clinical Research Unit, Division of Molecular and Gene Therapies, Menzies Health Institute Queensland, Griffith University

In January 2008, I was instrumental in establishing the Division of Molecular and Gene Therapies located at the Gold Coast. In my subsequent role as Head of the Clinical Research section I oversee many of the staff and students. We currently have about 9 staff and students working in this centre. I also play a key role in the writing of all grant applications and manuscripts. Some of the projects I am currently involved in are the genetics of type 2 diabetes, solid tumours therapeutics and Chinese traditional medicines.

In this role, I have been instrumental in establishing a collaborative link with the Guangdong Pharmaceutical University, Shandong University of Traditional Chinese Medicine and Heze University.

Since finishing my Ph.D. in 2003 I have had strong research outputs in a number of different fields ranging from diabetes research to cancer gene therapy. Whilst I have not had large numbers of publications, the majority of my publications are usually in journals with high impact factors. My total number of citations as per Google scholar is 1354 citations and with an h-index of 19. My number of citations as per Scopus is 771 citations and an h-index of 16.

My work has been published in a variety of topic areas but with a major focus on genetics and heredity. My total average impact factor for all of my publications is 5.53 which is significantly higher than the average for my focus area of genetics and heredity which stands at 2.54. This demonstrates the quality of my research in the international arena. Additionally, the majority of my journals are ranked in the first quartile indicating that an extended scientific community including members of the international medical body also contributes to the same journals. SJR values, indicative of both international influence and prestige of the journals in which my research has been published, is on average 3.13. The average for this field is only 0.98 which again indicating that my research is sitting above the average for my field which further demonstrates the level of quality of the research I have produced. Listed below are 12 of my key publications.

<i>Journal Name</i>	<i>Impact Factor</i>	<i>Quartile</i>	<i>Journal Rank</i>
<i>Molecular Cancer (n=1)</i>	11.350	Q1	6/198
<i>American Journal of Human Genetics (n=2)</i>	10.502	Q1	11/346
<i>Diabetes (n=2)</i>	7.720	Q1	6/239
<i>Cancer Letters (n=1)</i>	7.360	Q1	34/221
<i>Journal of Bone and Mineral</i>	5.854	Q1	13/232

<i>Research (n=2)</i>			
<i>Inorganic chemistry (n=1)</i>	4.850	Q1	5/68
<i>Molecular & Cellular Proteomics (n=1)</i>	4.828	Q1	23/440
<i>Bone (n=2)</i>	4.455	Q1	33/232
<i>Average of remaining publications</i>	2.43		
<i>Average</i>	5.53		

My cancer research has been awarded a significant amount of money from the Jinan Province in China (4 million Chinese Yuan) to set up a satellite lab in their city with the aim to run clinical trials. This money has been used to set up a lab in Jinan and employ a number of staff working towards clinical trials. This lab will provide the base for the clinical trial that we hope to carry out in China in the near future. The advantage of working in China is the significantly high population. In Jinan, there are entire cancer hospitals with 1000s of beds. Also, lung cancer is a significant problem in China and large numbers of research participants will be easier to recruit than here in Australia. However, the downside is the Chinese government is very strict in its policy that the funds are only to be spent in China.

Another indicator of my research quality, I have written many NHMRC, ARC and NIH grants. To date, all grants that I have played a significant role in writing have been assessed as “Fundable” by the panel. Assessors of our grants are usually unanimously positive in their assessment and use phrases like “well written application”, “truly novel” and “conceptually novel” approach to treating a highly significant cancer. I have also been asked to be an independent expert review for a number of NHMRC grants.

2018 – current **Executive Officer:** I am currently also serving as an adviser for Oriental Care and Senior Helpers Brisbane. Oriental Care is a not-for-profit NDIS provider company in order to provide the best culturally sensitive, quality disability care services to members of the Australian community in Queensland. It is a registered NDIS Provider and Home Care package provider which complies with all Queensland and Commonwealth Government requirements for the delivery of quality and safe support services to clients at their home or communities.

As part of my responsibilities I assist the CEO in the organisational management of the company and oversee the supervision and management of all staff. More specifically I am required to:

- Lead the development of company policy and procedures
- Regularly review of policies and procedures of the organisation and ensure policies and procedures are in line with relevant sector standards and legislation
- Contribute to and lead strategic planning processes and assist in

- continuous quality improvement leading to best practice
- Have excellent governance knowledge and have experience in the leadership of a large workforce.
- Maintain effective working relationships with key stakeholders, to build and participate in key partnerships and participate actively in community networks.
- Demonstrated ability to provide leadership and support to staff working within a team context.

2008 - 2010 **Course convenor:** Anatomy and Physiology, School of Nursing and Midwifery, Griffith University

As course convenor of Anatomy and Physiology, I was responsible for the development and presentation of all resources for the course. These resources along with my enthusiasm in teaching has seen an improvement of the overall pass rate for this course which traditionally has had a high fail rate. Also my efforts and enthusiasm in teaching resulted in many nominations for “**Excellence in Teaching Awards**” in 2008, 2009 and 2010. In 2010 I also received a **Commendation for outstanding performance** in enhancing the quality of student learning. This is recognition of my excellent teaching during 2009 based on student evaluations. These awards were given to lecturers who received evaluations of their teaching in the top 5% of the University in two or more courses over two semesters.

I was responsible for all administrative aspects of all units I taught, as well as making a significant contribution to the administration of the program.

I strongly participated in the School of Nursing and Midwifery curriculum planning for both the biosciences as well as other aspect of the program. I subsequently coordinated the review panel for Anatomy and Physiology. More specifically, I wrote the new Anatomy and Physiology course outlines.

2004 – 2008 **Senior Research Fellow.**
Diabetes and Cardiovascular Research Laboratories, Prince Charles Hospital. Employer - Associate Professor Joanne Shaw.

As senior scientist of the Diabetes Research Laboratories, I was required to manage an NHMRC grant and a NIH grant totalling over 1 million dollars. These funds were meant to last for two years, however, through my planning and budget I managed to kept us operating for four years. I was also required to oversee all projects and ensure their progress. As part of my responsibility I was involved in training and supervising staff, bench work and coordinating the overall direction of the research projects. I was also responsible for the administration of our research funds.

I was responsible for three main projects:

- 1) The genetics of type 2 diabetes in an Indigenous Australian community.
- 2) Implemented a lifestyle intervention program in an Indigenous Australian community to reduce the burden of type 2 diabetes.
- 3) The genetics of type 2 diabetes in a Caucasian/Pacific Islander population.

As the senior research fellow, I was responsible for leading the preparation of teaching material for an indigenous community based education program to reduce the burden of type 2 diabetes and its associated complications. At these opportunities I had the opportunity to present our research results to the community. Presentations had to be designed to suit the general public with no knowledge of medicine or science. This program was deemed to be a success as shown in the overall reduction of many of the cardiovascular risk markers within the community.

During my time leading this research group I also served as a “Problem Based Learning” tutor for the School of Medicine for first year medical students at the University of Queensland.

2002 – 2004 **Research Fellow.**
Infectious Diseases Program, School of Life Sciences, Queensland University of Technology, Brisbane, Australia. Employer – Professor Peter Timms.

Persistent *Chlamydia pneumoniae* infection has been implicated in the etiology of atherosclerosis, however, a direct causal role remains to be elucidated. My role was to try to determine the link between atherosclerosis and *Chlamydia pneumoniae*. Another important part of my position was to analysis data generated and present it in papers, presentations and posters, as well as assist in the writing of an NIH grant application.

1998 – 2003 **Doctor of Philosophy Candidate.**
Department of Diabetes and Endocrinology, Princess Alexandra Hospital. Supervisor - Associate Professor Joanne Shaw.

In this project I elucidated the genetic basis of Paget’s disease of bone through microsatellite analysis. A mutation in a gene encoding *sequestosome SQSTM1/p62* was found in affected family members with Paget’s disease.

1996 – 1997 **First Class Honours, Vacation Scholarship, Third Year Project.**
CSIRO Division of Tropical Agriculture, Brisbane, Australia. Supervisor - Dr Ross Tellam.

The aim of my third year project, vacation scholarship and honours was to localise and sequence the bovine *obese* gene and the corresponding promoter region.

HDR Student Supervision

PhD

- **Principle supervisor:** Ian Parker, School of Physiotherapy
- **Co-supervisor:** Muneera Anwer, Griffith University
- **Co-supervisor:** Paniz Siminzar, Griffith University
- **Co-supervisor:** Ji Qi, Griffith University
- **Co-supervisor:** Abu Zulfiker, Griffith University
- **Co-supervisor:** Caroline Hinton, Griffith University
- **Co-supervisor:** Mohsen Sohrabi, Griffith University
- **Co-supervisor:** Kai Zhang, Griffith University
- **Co-supervisor:** Gang Lui, Griffith University
- **Co-supervisor:** Chun Li, Griffith University
- **Co-supervisor:** Bruce Xu, Griffith University
- **Co-supervisor:** Siyu Cao, Griffith University
- **Co-supervisor:** Chun Li, Griffith University
- **Associate supervisor:** Lionel Chan, University of Queensland
- **Associate supervisor:** Shelly Walker, University of Queensland

Completed Masters

- **Co-supervisor:** Yeh Sze Ong, Griffith University
- **Co-supervisor:** Sha Yu, Griffith University
- **Co-supervisor:** Brock Grant, Griffith University
- **Co-supervisor:** Yuduo Wang, Griffith University
-

Honours

- Moksha Patel, School of Biomedical Science, Griffith University
- James Sikkema, Eleanor Swavley, Karrie Field, School of Physiotherapy
- Christopher Ramalu, School of Physiotherapy
- Kate Byrush, School of Physiotherapy
- Bonnie Miller, School of Physiotherapy
- Patrick Banney, School of Physiotherapy
- Danielle Hollis, School of Physiotherapy
- Jonathan Vine, School of Physiotherapy
- Luran McHenry, School of Physiotherapy

2005 Supervised an international student on a research elective in the Diabetes Research Laboratories. The title of his project was “The search for genes for Paget’s disease of bone”. During the course of my PhD and Research Fellow position I have had the opportunity to train and supervise a number of students.

2003 – 2004 Laboratory demonstrator at QUT for biochemistry.

2003 – 2004 During the course of my employment at Queensland University of Technology, I was responsible for the examination of a number of Honours students written and oral presentations.

Funding Sources and Awards

Since commencing at as senior researcher within the diabetes research laboratories I have been responsible for writing or co-writing all grants. Over the years I have been responsible for writing grants that have award us approximately 1.5 million dollars within Australian and 4 million within China. As I have only commenced my cancer research collaboration in 2006 I have purposely kept my name off the Chief Investigator list until my track record is comparable to my peers in cancer therapy. However, I have played a major role in writing and submitting all grants from our institute.

- 2018 ACU case study grant. For the development of video case studies for the School of Physiotherapy. \$30,000
- 2016 Preclinical and clinical trials of clostridial oncolytic cancer therapy. Jinan Government, China. 4 million Yuan.
- 2014 Immunological evaluation of a novel targeted therapy for primary and metastatic non-small cell lung cancer. Griffith Health Institute. \$10,000
- 2013 Animal modelling of lung cancer. Griffith Health Institute. \$10,000
- 2012 Faculty Research Grant. ACU. \$10,000
- 2012 Anaerobic bacteria for cancer therapy. Griffith Health Institute. \$10,000
- 2011 Research Support Team grant. ACU. \$40,000
- 2011 Labelling of bacteria for in vivo imaging. Griffith Health Institute. \$10,000
- 2010 Targeting Small Noncoding RNAs & Bone Marrow Mediated Angiogenesis in Breast Cancer. NHMRC. \$560,000
- 2008 Bugging lung cancer with siRNA. Smart state fellowship. \$750,000
- 2010 **Nomination for Griffith University Excellence in Teaching award.**
- 2009 **Commendation for outstanding performance in enhancing the quality of student learning. This is recognition of my excellent teaching during 2009 based on student evaluations.**
- 2009 **Nomination for Griffith University Excellence in Teaching award.**

- 2008 **Nomination for Griffith University Excellence in Teaching award.**
- 2007 The Prince Charles Hospital Foundation. \$47,850 for the project titled “Evaluation of emerging cardiovascular risk markers on mortality and morbidity in an Indigenous Australian population after 10 years (ECARDAMM-10)”
- 2007 The Prince Charles Hospital Foundation. \$33,000 for the project titled “High density SNP analysis of a region of chromosome 12q24 for association with type 2 diabetes”
- 2006 NHMRC equipment grant. \$87,850
- 2006 The Prince Charles Hospital Foundation. \$34,870 for the project titled “Protein and mRNA expression profiles of osteoclast-like cells in patients with Paget’s disease of bone”
- 2006 The Prince Charles Hospital Foundation. \$30,250 for the project titled “Identification of a gene in the *PDB7* locus for Paget’s disease of bone”
- 2002 Travel Grant to attend the Australian and New Zealand Bone and Mineral Bone and Mineral Society Annual Conference.
- 2001 **Roger Melick Young Investigator of the year** – Australian and New Zealand Bone and Mineral Society.
- 2001 Princess Alexandra Hospital Foundation Grant. \$5,000 for the project titled “The Localisation of a Gene for Paget’s Disease of Bone”.
- 2001 Travel Grant to attend the Australian and New Zealand Bone and Mineral Bone and Mineral Society Annual Conference.
- 1999 Travel Grant to attend the Endocrine Society Annual Conference.
- 1998 Australian Postgraduate Award with Stipend.
- 1997 First Class Honours.
- 1996 - 1997 Vacation Scholarship.
- 1995 Golden Key National Honours Society (awarded for academic excellence in my undergraduate degree).

Publications

Books and Chapters

Book editor - Good D, and MQ Wei. Novel Gene Therapy Approaches. InTech - Open Access Publisher, ISBN 978-953-51-0966-2. February 13, 2013

Sakiragaoglu O, **Good D**, and Wei M. (2013). Cancer Gene Therapy with small oligonucleotides, *Novel Gene Therapy Approaches*, Good D, and MQ Wei Eds, InTech - Open Access Publisher, **Chapter 14**, ISBN 978-953-51-0966-2.

Good D, J Anne, W Duan and MQ Wei. (2011). Cancer Gene Therapy - developments and future perspectives, in *Gene Therapy - developments and future perspectives*, Chunsheng Kang Ed, InTech - Open Access Publisher, ISBN 978-953-307-617-1.

Nuyen T, Cao S, **Good D** and Wei M (2009). Future developments in electroporation: Bacterial targeted tumour therapy. *Electroporation*, Enrico P Spugnini (Ed). Nova Science Publishers, New York. ISBN 978-1-61668-327-6

Mengesha A, Dubois L, Chiu R, Paesmans K, Wouters Bradley G, Lambin P, Theys J, Wei M, Good D, Anne J. Bacterial-mediated cancer therapy: Potential and limitations. *Use of Non-Pathogenic Bacteria as Vectors for Targeted Gene Expression in Cancer Gene Therapy*

Publications in Refereed Journals

J Kaur, J Elms, AL Munn, **D Good**, MQ Wei. Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. *Critical Reviews in Oncology/Hematology*. 2021 July

Yang B, **Good D**, Mosaiab T, Liu W, Ni G, Kaur J, Liu X, Jessop C, Yang L, Fadhil R, Yi Z, Wei MQ. Significance of LL-37 on Immunomodulation and Disease Outcome. *Biomed Res Int*. 2020 May 16;2020:8349712.

Fadhil RS, Wei MQ, Nikolarakos D, **Good D**, Nair RG. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma. *PLoS One*. 2020 Mar 24;15(3):e0221779.

Ni G, Wang Y, **Good D**, Yuan J, Pan X, Wei J, Liu X, Wei MQ. The Dosage of the Derivative of *Clostridium Ghonii* (DCG) Spores Dictates Whether an IFN γ /IL-9 or a Strong IFN γ Response Is Elicited

in TC-1 Tumour Bearing Mice. *Biomed Res Int.* 2019 Apr 28;2019:1395138.

Jiang S, **Good D**, Wei MQ. Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants. *Int J Mol Sci.* 2019 Jul 11;20(14):3403.

Liu W, Yang B, Yang L, Kaur J, Jessop C, Fadhil R, **Good D**, Ni G, Liu X, Mosaib T, Yi Z, Wei MQ. Therapeutic Effects of Ten Commonly Used Chinese Herbs and Their Bioactive Compounds on Cancers. *Evid Based Complement Alternat Med.* 2019 Sep 15;2019:6057837.

Good DA, Duffy DL, Good M, Xia Guo C, Busfield F, Shaw A, Shaw JTE. Noncoding Variations in the Gene Encoding Ceramide Synthase 6 are Associated with Type 2 Diabetes in a Large Indigenous Australian Pedigree. *Twin Res Hum Genet.* 2019 Apr;22(2):79-87.

Qi J, Zulfiker AHM, Li C, **Good D**, Wei MQ. The Development of Toad Toxins as Potential Therapeutic Agents. *Toxins (Basel).* 2018; 10(8).

Zulfiker AH, Hashimi SM, **Good DA**, Grice ID, Wei MQ. Cane Toad Skin Extract-Induced Upregulation and Increased Interaction of Serotonin 2A and D₂ Receptors via G_{q/11} Signaling Pathway in CLU213 Cells. *J Cell Biochem.* 2017; 118(5): 979-993.

Sohrabi M, Nair RG, Samaranayake LP, Zhang L, Zulfiker AH, Ahmetagic A, **Good D**, Wei MQ. The yield and quality of cellular and bacterial DNA extracts from human oral rinse samples are variably affected by the cell lysis methodology. *J Microbiol Methods.* 2016; 122:64-72.

Li C, Hashimi S, Cao S, Qi J, **Good D**, Duan W, Wei M. Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo. *BMC complementary and alternative medicine.* 2015; 15(1): 207

Qi J, Tan C, Hashimi S, Zulfiker Abu, **Good D**, Wei M. Toad Glandular Secretions and Skin Extractions as Anti-Inflammatory and Anticancer Agents. *Evidence-Based Complementary and Alternative Medicine.* 2014: 312684

Zhang K, Xu Z, Lu J, Tang Z, Zhao H, **Good D**, Wei M. Potential for layered double hydroxides-based, innovative drug delivery systems. *International journal of molecular sciences.* 2014; 15(5): 7409-7428

Li C, Hashimi S, Cao S, Mellick A, Duan W, **Good D**, Wei, M. The mechanisms of chansu in inducing efficient apoptosis in colon cancer

cells. *Evidence-Based Complementary and Alternative Medicine*. 2013;849054

Li C, Hashimi S, **Good D**, Cao S, Duan W, Plummer P, Mellick A, Wei M. Apoptosis and microRNA aberrations in cancer. *Clinical and Experimental Pharmacology and Physiology*. 2012; 39(8): 739-746

Umer B, **Good D**, Anné J, Duan W, Wei M. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. *Journal of toxicology*. 2012:862764. DOI: 10.1155/2012/862764

Liu G; Fan W, Miao X, Xiao Y, **Good D**, Wei M. Sequential release of BMP-7 and VEGF from the PLGA/AK-gelatin composite scaffolds. *Journal of Biomimetics, Biomaterials and Tissue Engineering*. 2011; 11; 81-91

Xie J, Cao S, **Good DA**, Wei M, Ren X. A Combination of Fluorescent Dye and Zn-S Nanocluster and Its Biological Application on Stain Bacteria. *Inorg Chem*. 2010 Feb 15;49(4):1319-21.

Timms P, **Good D**, Wan C, Theodoropoulos C, Mukhopadhyay S, Summersgill J, Mathews S. Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for *Chlamydia pneumoniae*. *Journal of microbiology, immunology, and infection*. 2009; 42(1): 27 - 37

Qin Yao, Xun Qu, Qifeng Yang, **D. Good**, Shuzhen Dai, Beihua Kong and M. Wei. Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models. *Molecular Cancer*. 2009; vol.8, no.78.

Weijian Bei, Xinghong Zhu, M. Wei, Chuyuan Li, Linqun Zang, Jiao Guo, Wenlie Peng, Anlong Xu, **D. Good**, Yinming Hu, Wei Wu and Dehui Hu. Neuroprotective effects of a standardized flavonoid extract from *Diospyros kaki* leaves. *Journal of Ethnopharmacology*. 2009; vol.126.

Wei MQ, Ren A, **Good D** and Anne J. “Trojan horse” vectors based on anaerobic bacteria for cancer gene therapy. *Gene Vaccine & Therapy*. 2008; 6:8

Wei MQ, Mengesha A, **Good D**, Anné J. Bacterial targeted tumour therapy – dawn of a new era. *Cancer Letters*. 2008; 259:16 – 27.

Wei MQ, Ruimei R, **Good D**, Anné J. Clostridial spores as live ‘Trojan horse’ vectors for cancer gene therapy: comparison with viral delivery systems. *Genetic Vavvines and Therapy*. 2008; 6:8

D. Good, John Cardinal, Robert S Ware, Lisa Marks, Janine B Kesting, Lionel CK Chan, Joanne TE Shaw. Susceptibility to insulin

resistance in indigenous Australians may be down stream of resistin. *International Journal of Diabetes and Metabolism*. 2008 16: 1-6 .

Chan LCK, Ware R, Kesting J, Marczak M, **Good D**, Shaw JTE. Association between anthropometric measures of obesity and cardiovascular risk markers in a self-selected group of Indigenous Australians. *European Journal of Cardiovascular Prevention and Rehabilitation* 2007; 14(4):515-7.

Chan LCK, Ware R, Kesting J, Marczak M, **Good D**, Shaw JTE. Short term efficacy of a lifestyle intervention programme on cardiovascular health outcome in overweight Indigenous Australians with and without type 2 diabetes mellitus - The Healthy Lifestyle Programme (HELP). *Diabetes Research and Clinical Practice* 2007; 75:65-71

Chan LC, Ware RS, Kesting J, Marczak M, **Good D**, Shaw JT. Association between anthropometric measures of obesity and insulin resistance in a self-selected group of Indigenous Australians. *Heart, Lung and Circulation*. 2007; 16(4):303-4.

Mukhopadhyay S, **Good DA**, Miller RD, Graham JE, Mathews SA, Timms P and Summersgill JT. (2006) Identification of chlamydia pneumoniae proteins in the transition from reticulate to elementary body formation. *Molecular and Cellular Proteomics*. 2006 Dec; 5(12):2311-2318.

Shaw JTE, Chan LCK, **Good D**. Maturity onset diabetes of the young. *Diabetes Management* 2006; 15:7 (review)

Good DA, Busfield F, Fletcher B, Lovelock PK, Duffy D, Kesting J, Andersen J, Shaw J.T.E. Identification of *SQSTM1/p62* mutations in familial Paget's disease in Australian pedigrees. *Bone*. 2004 Jul;35(1):277 - 282

Good DA, Busfield F, Fletcher BH, Duffy DL, Kesting JB, Andersen J, Shaw JT. Linkage of Paget's disease of bone to a novel region on human chromosome 18q23. *American Journal of Human Genetics*. 2002 Feb; 70(2):517-25.

Busfield F, Duffy DL, Kesting JB, Walker SM, Lovelock PK, **Good D**, Tate H, Watego D, Marczak M, Hayman N, Shaw JT. A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. *American Journal of Human Genetics*. 2002 Feb; 70(2):349-57.

Good D, Busfield F, Duffy D, Lovelock PK, Kesting JB, Cameron DP, Shaw JT. Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree. *Journal of Bone Mineral Research*. 2001 Jan; 16(1):33-8.

Shaw JT, Lovelock P, Kishimoto-Hashiramoto M, Cardinal J, **Good D**, Kesting J, Wainwright B. Localisation of a novel susceptibility gene for late-onset NIDDM to a 2cM region of chromosome 12. *Diabetes*. 1999; 48

Oral Presentations

- 2013 **Invited speaker:** Shandong University of Medical Science. Presenting on my pain and cancer therapeutics research.
- 2006 Australian Diabetes Association annual meeting. Gold Coast, August 23-25. “Adipokine levels in a large pedigree of Indigenous Australians with high prevalence of type 2 diabetes mellitus and central obesity”.
- 2005 Australian Diabetes Association annual meeting. Perth, September 7-9. “A genome-wide search for type 2 diabetes susceptibility genes in an indigenous Australian pedigree”.
- 2004 **Invited speaker** at the Australian Society for Microbiology. Moreton Bay Research Facility, North Stradbroke Island, 31st July 2004. “Transcriptome and Proteome analysis of *Chlamydia pneumoniae* gene expression modulated by IFN- γ ”.
- 2003 Infection disease program meeting, School of Life Sciences, Queensland University of Technology, Brisbane, Australia. “Differential expression of *Chlamydia pneumoniae* genes modulated by IFN- γ ”.
- 2002 Australian and New Zealand Bone and Mineral Society annual meeting, Adelaide, October 6-9. Competing for the Young Investigators Award. “Single Base-Pair Deletion of a Gene Encoding *sequestosome1* (*SQSTM1/p62*) in Paget’s Disease of Bone”.
- 2001 Australian and New Zealand Bone and Mineral Society annual meeting, Auckland, October 7-10. Competing for the Young Investigators Award. “Paget’s Disease of Bone: Linkage to a Novel Region on Human Chromosome 18q23”.
- 2001 Southeast Queensland Endocrine Meeting, “Genetic Loci for Paget’s disease”.
- 2000 PA week Talks, “The Localisation of a Gene for Paget’s Disease of Bone”.
- 2000 Southeast Queensland Endocrine Meeting, “The Characterisation of the Genetic Basis for Paget’s Disease of Bone”.
- 1999 Endocrine Society of Australia annual meeting, Melbourne. “The Characterisation of the Genetic Basis for Paget’s Disease of Bone”.

- 1999 PA week Talks, “The Genetic Basis for Paget’s Disease of Bone”.
- 1999 Southeast Queensland Endocrine Meeting, “The Characterisation of the Genetic Basis for Paget’s Disease of Bone”.
- 1998 Southeast Queensland Endocrine Meeting, “Genetic Basis for Paget’s disease”.

Poster Presentations

- 2004 **Good DA**, Mukhopadhyay S, Theodoropoulos C, Miller RD, Mathews SA, Summersgill JT and Timms P. Transcriptome and Proteome analysis of *Chlamydia pneumoniae* gene expression modulated by IFN- γ . 5th Meeting of the European Society for Chlamydia Research, Budapest, Hungary.
- 2004 Mukhopadhyay S, Sullivan ED, Clark AP, Mathews SA, **Good DA**, Timms P, Miller RD, and Summersgill JT. Proteomic analysis of persistent *Chlamydia pneumoniae* in Hep2 cells induced by IFN- γ and other cytokines. 5th Meeting of the European Society for Chlamydia Research, Budapest, Hungary.
- 2004 Mukhopadhyay S, **Good DA**, Clark AP, Sullivan ED, Miller RD, Hogan R, Polkinghorn A, Mathews SA, Timms P and Summersgill JT. Proteomic and transcriptomic analysis of interferon- γ mediated persistence in *Chlamydia pneumoniae*. American Society of Microbiology.
- 2000 **Good DA**. The Genetic Basis of Paget’s Disease. Princess Alexandra Hospital Research Foundation display.
- 1998 **Good DA**. The Characterisation of a Peritrophic Membrane Glycoprotein ‘Peritrophin 30’, From the Larvae of *Lucilia cuprina*. East Coast Protein Group conference.

Poster Judge

- 2004 Poster Judge for the Australian Society of Medical Research Student Conference.

Society membership

- 1999 Endocrine Society of Australia
- 2000 - 2002 Australian and New Zealand Bone and Mineral Society
- 1995 – current Golden Key National Honours Society
- 2004 – 2008 Australian Diabetes Society

Referees:

Professor Ming Wei
School of Medical Science
Griffith Institute of Health and Medical Research
Griffith University, Gold Coast campus
Southport, 4222
Ph: (0422) 888 780
Email: m.wei@griffith.edu.au
ALSO: CEO of Oriental Care and Senior Helpers Brisbane

Jennifer Murphy
Former: Course Co-ordinator for the Discipline of Physiotherapy, School of Allied Health, Australian Catholic University
Current: Senior Physiotherapist Mater Hospital
Ph: (0410) 752 000
Email: jennifer.murphy@mater.org.au

Cath Jameson
Former: Head of Anatomy ACU
School of Allied Health,
Australian Catholic University
Ph: (0402) 753 150
Email: cath.jameson@acu.edu.au

Associate Professor Joanne Shaw
Private Practice Clinic
Level 4, Administrative Building
Prince Charles Hospital,
Chermside QLD 4032
Ph: (0438) 611 784
Email: jtshaw@gmail.com